Nexentis Technologies price to book ratio NXTS
Market value divided by the book value of the company's net assets, since 2026.
- Today, Nov 2, 2026
- 0.4×
- Peer median
- 0.3×
Nexentis Technologies' price to book ratio is 0.4× as of Nov 2, 2026.
It has traded since Jan 30, 2026, and over that time its price to book ratio ranged from 0.1× in Jul 2026 to 1.5× in Aug 2026.
The median for 10 large drugmakers of a similar size is 0.3×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.4× | 0.1× | 1.5× |
Against its peers
Companies in Drug Manufacturers - General nearest Nexentis Technologies' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| NXTSNexentis Technologies | 0.4× |
| LNAILunai Bioworks | n/m |
| DCOYDecoy Therapeutics | 0.2× |
| ARTLArtelo Biosciences | 0.2× |
| SBFMSunshine Biopharma | 0.0× |
| GOVXGeoVax Labs | 0.7× |
| MTNBMatinas BioPharma | 0.7× |
| VBIOValion Bio | 0.1× |
| LABTLakewood-Amedex Biotherapeutics | n/m |
| KAPAKairos Pharma, LTD. | 0.4× |
| OGENOragenics | 0.5× |
| Peer median | 0.3× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Nexentis Technologies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.